Typically lesions identified with contrast-enhanced mammography are sent to MRI for biopsy, but now with Serena Bright, the industry-first contrasted enhanced biopsy-guided solution, breast biopsy procedures can be performed with the same mammography equipment, with the same staff and in the same room as the screening or diagnostic mammogram. Key to this technology’s application is GE Healthcare’s SenoBright HD Contrast Enhanced Spectral Mammography, a diagnostic imaging tool that delivers high sensitivity for more accurate breast cancer diagnosis. By highlighting areas of unusual blood flow to help localize lesions that need biopsy, Serena Bright can help improve radiologists’ diagnostic confidence. Serena Bright will be commercially available in the United States in October 2020.
1. Contrast-Enhanced Mammography: A Systematic Guide to Interpretation and Reporting. AJR https://www.ajronline.org/doi/full/10.2214/AJR.17.19265
2. 510(k) Premarket Notification Submission: https://www.accessdata.fda.gov/cdrh_docs/pdf19/K193334.pdf